ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2583

Unexpected High Prevalence of Cardiac Disease in Patients with Ankylosing Spondylitis

S.C. Heslinga1,2, Thelma C. Konings3, Irene E. Van der Horst - Bruinsma4, M.L. John4 and Mike T. Nurmohamed2, 1Internal Medicine, VU University Medical Center, Amsterdam, Netherlands, 2Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, 3Cardiology, VU University Medical Center, Amsterdam, Netherlands, 4Rheumatology, VU University Medical Center, Amsterdam, Netherlands

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Ankylosing spondylitis (AS) and cardiovascular disease

  • Tweet
  • Email
  • Print
Session Information

Title: Spondyloarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment III

Session Type: Abstract Submissions (ACR)

Background/Purpose

Ankylosing spondylitis (AS) is associated with an increased cardiovascular (CV) risk that is caused by accelerated atherosclerosis as well as specific cardiac manifestations: valvular disease, conduction disturbances and congestive heart failure due to decreased ventricular function. In this study we investigated the prevalence of cardiac disease in AS patients with high disease activity.

Methods

We performed a cross sectional study in patients with AS eligible for treatment with TNF blocking therapy. Patients were screened for cardiac disease using standard transthoracic echocardiography that included two-dimensional, three-dimensional and M-mode echocardiography, spectral Doppler, color Doppler and tissue Doppler imaging. The ejection fraction (EF) was used to assess systolic left ventricular (LV) function, with systolic LV dysfunction defined as EF<50%. For diastolic LV function a combination of echocardiographic measurements, i.e. peak early diastolic filling velocity (E), late diastolic filling velocity (A), E/A ratio, early diastolic mitral annular velocity (E’), deceleration time (DT) and isovolumetric relaxation time (IVRT) were used. Based on these parameters diastolic LV dysfunction is graded into three categories: mild (grade I), pseudonormal (grade II) and restrictive (grade III). Valvular and aortic abnormalities were evaluated according to the current echocardiographic guidelines. Data was compared with data from literature using one-sample t-test.

Results

Forty-three consecutive AS patients were included with a mean age of 43±12 years and a mean disease duration of 10±12 years. In total, 10 out of 43 (23%) patients had diastolic LV dysfunction grade I, of which one was female. This was significantly higher compared to literature, in which the prevalence of diastolic LV dysfunction grade I is approximately 5% in an age matched control group (p<0.01)1. Two patients had a prior myocardial infarction of which one had systolic LV dysfunction, with an EF of 49%. Three patients had mild aortic regurgitation and seven other patients had mild mitral regurgitation. Five patients had mild aortic dilatation. Overall, 19 out of 43 AS patients (44%) had some form of cardiac dysfunction or disease which is substantially higher compared to the general population, as the prevalence of cardiac disease in the general population is approximately 8% 2.

 

Conclusion

Patients with AS have an increased prevalence of cardiac disease compared with the general population, with increased prevalence’s of left ventricular dysfunction and valvular disease. This increased prevalence may increase CV risk in AS patients. As cardiac disease could be attributable to the general inflammation process affecting the heart, further studies are warranted that investigate whether or not anti-inflammatory treatment, such as TNF blockers, improves cardiac function or prevents early cardiac complications. Also, the impact of (mandatory) screening AS patients with echocardiography on CV disease should be investigated.


Disclosure:

S. C. Heslinga,
None;

T. C. Konings,
None;

I. E. Van der Horst – Bruinsma,
None;

M. L. John,
None;

M. T. Nurmohamed,

Abbott, Roche, Pfizer,

8.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/unexpected-high-prevalence-of-cardiac-disease-in-patients-with-ankylosing-spondylitis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology